Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer-Reference-Cited by-同舟云学术

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Published:2011-10-07 Issue:21 Volume:54 Page:7579-7587
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sutherlin Daniel P.¹,Bao Linda¹,Berry Megan¹,Castanedo Georgette¹,Chuckowree Irina²,Dotson Jenna¹,Folks Adrian²,Friedman Lori¹,Goldsmith Richard¹,Gunzner Janet¹,Heffron Timothy¹,Lesnick John¹,Lewis Cristina¹,Mathieu Simon¹,Murray Jeremy¹,Nonomiya Jim¹,Pang Jodie¹,Pegg Niel²,Prior Wei Wei¹,Rouge Lionel¹,Salphati Laurent¹,Sampath Deepak¹,Tian Qingping¹,Tsui Vickie¹,Wan Nan Chi²,Wang Shumei¹,Wei BinQing¹,Wiesmann Christian¹,Wu Ping¹,Zhu Bing-Yan¹,Olivero Alan¹

Affiliation:

1. Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

2. Piramed Pharma, 957 Buckingham Avenue, Slough, Berks SL1 4NL, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm2009327

Reference35 articles.

1. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

2. The Phosphoinositide 3-Kinase Pathway